Compare CMPS & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPS | DNA |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.6M | 607.1M |
| IPO Year | 2020 | N/A |
| Metric | CMPS | DNA |
|---|---|---|
| Price | $7.61 | $9.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $18.71 | $10.50 |
| AVG Volume (30 Days) | ★ 3.6M | 973.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.25 | $5.00 |
| 52 Week High | $8.90 | $17.58 |
| Indicator | CMPS | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 52.27 |
| Support Level | $5.95 | $8.19 |
| Resistance Level | $8.55 | $10.16 |
| Average True Range (ATR) | 0.56 | 0.77 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 69.40 | 65.28 |
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.